Synta announces Executive Management changes, appoints Dr Paul Friedman Director

04-03-2014 Business Wire HealthComments (0)

PharmaceuticalSynta PharmaceuticalsUSA

Synta Pharmaceuticals (NASDAQ: SNTA) today announced that Safi Bahcall has resigned as President, Chief Executive Officer and a member of the Board of Directors, effective immediately, and has been replaced by a newly formed Executive Committee of the Board. The Committee will be chaired by Keith Gollust, the Company’s Chairman of the Board of Directors, and include current Director Robert Wilson, retired Vice Chairman of Johnson & J

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top